ADMA Financials: ADMA Biologics Inc AI Analysis

Home

Stock

ADMA

Financials

ADMA Financial

ADMA Biologics Inc

Overview Forecast Earnings Dividends Financials

360

Report

Final Score

Key Stats

Prev.Close

$11.33

Open

$11.38

Day's Range

$8.62 - $11.45

52 week range

$8.62 - $25.67

Volume

32.4M

Avg.Volume

2.8M

Dividend yield

EPS (TTM)

0.85

Market Cap

$2.2B

What is ADMA?

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

ADMA Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	510	510	426	258	154	80
Revenue Growth (YoY)	20%	20%	65%	68%	93%	90%
Cost of Revenue	217	217	206	167	118	79
Gross Profit	292	292	219	91	35	1
Selling, General & Admin	96	96	78	62	70	55
Research & Development	4	4	1	3	3	3
Operating Expenses	101	101	80	66	74	59
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	182	182	125	-28	-65	-71
Income Tax Expense	35	35	-71	--	--	--
Net Income	146	146	197	-28	-65	-71
Net Income Growth	-26%	-26%	-803.99%	-56.99%	-8%	-5%
Shares Outstanding (Diluted)	243.14	244.9	243.34	223.97	197.9	139.6
Shares Change (YoY)	-2%	1%	9%	13%	42%	62%
EPS (Diluted)	0.59	0.6	0.81	-0.12	-0.33	-0.51
EPS Growth	-26%	-26%	-744%	-62%	-35%	-42%
Free Cash Flow	27	27	110	3	-73	-125
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	57.25%	57.25%	51.4%	35.27%	22.72%	1.25%
Operating Margin	37.45%	37.45%	32.39%	9.3%	-25.32%	-72.5%
Profit Margin	28.62%	28.62%	46.24%	-10.85%	-42.2%	-88.75%
Free Cash Flow Margin	5.29%	5.29%	25.82%	1.16%	-47.4%	-156.25%
EBITDA	199	199	146	32	-32	-53
EBITDA Margin	39.01%	39.01%	34.27%	12.4%	-20.77%	-66.25%
D&A For EBITDA	8	8	8	8	7	5
EBIT	191	191	138	24	-39	-58
EBIT Margin	37.45%	37.45%	32.39%	9.3%	-25.32%	-72.5%
Effective Tax Rate	19.23%	19.23%	-56.8%	--	--	--

Follow-Up Questions

What are ADMA Biologics Inc's key financial statements?



According to the latest financial statement (Form-10K), ADMA Biologics Inc has a total asset of $624, Net profit of $146

What are the key financial ratios for ADMA?



ADMA Biologics Inc's Current ratio is 4.27, has a Net margin is 28.62, sales per share of $2.08.

How is ADMA Biologics Inc's revenue broken down by segment or geography?



ADMA Biologics Inc largest revenue segment is ADMA BioManufacturing, at a revenue of 415,806,000 in the most earnings release.For geography, United States is the primary market for ADMA Biologics Inc, at a revenue of 410,148,000.

Is ADMA Biologics Inc profitable?



yes, according to the latest financial statements, ADMA Biologics Inc has a net profit of $146

Does ADMA Biologics Inc have any liabilities?



yes, ADMA Biologics Inc has liability of 146

How many outstanding shares for ADMA Biologics Inc?



ADMA Biologics Inc has a total outstanding shares of 237.87

ADMA Biologics Inc (ADMA) Financial

ADMA Stock Price Chart